Gregg W Stone

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi request reprint Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    Lancet 369:907-19. 2007
  2. doi request reprint Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction)
    Gregg W Stone
    Columbia University Medical Center, New York, New York The Cardiovascular Research Foundation, New York, New York Electronic address
    J Am Coll Cardiol 63:15-20. 2014
  3. doi request reprint Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study
    Gregg W Stone
    Columbia University Medical Center, New York Presbyterian Hospital, New York, NY 10022, USA
    Lancet 382:614-23. 2013
  4. doi request reprint Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial
    Gregg F Rosner
    New York Presbyterian Hospital, Columbia University Medical Center, Cardiovascular Research Foundation, NY 10022, USA
    Circulation 125:2613-20. 2012
  5. doi request reprint Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial
    Gregg W Stone
    Columbia University Medical Center and New York Presbyterian Hospital, New York, New York 10022, USA
    JAMA 307:1817-26. 2012
  6. doi request reprint Impact of major bleeding and blood transfusions after cardiac surgery: analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    Am Heart J 163:522-9. 2012
  7. ncbi request reprint Effect of prolonged thienopyridine use after drug-eluting stent implantation (from the TAXUS landmark trials data)
    Gregg W Stone
    The Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 102:1017-22. 2008
  8. ncbi request reprint Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial
    Gregg W Stone
    Department of Cardiology, Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10032, USA
    JAMA 295:1253-63. 2006
  9. doi request reprint Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction
    Gregg W Stone
    Columbia University Medical Center, New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY 10022, USA
    Circ Cardiovasc Interv 2:366-75. 2009
  10. ncbi request reprint Bivalirudin for patients with acute coronary syndromes
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    N Engl J Med 355:2203-16. 2006

Collaborators

Detail Information

Publications107 found, 100 shown here

  1. ncbi request reprint Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    Lancet 369:907-19. 2007
    ..The aim of this study was to assess anticoagulation with the direct thrombin inhibitor bivalirudin during percutaneous coronary intervention in individuals with moderate and high-risk acute coronary syndromes...
  2. doi request reprint Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction)
    Gregg W Stone
    Columbia University Medical Center, New York, New York The Cardiovascular Research Foundation, New York, New York Electronic address
    J Am Coll Cardiol 63:15-20. 2014
    ....
  3. doi request reprint Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study
    Gregg W Stone
    Columbia University Medical Center, New York Presbyterian Hospital, New York, NY 10022, USA
    Lancet 382:614-23. 2013
    ..We aimed to determine the relation between platelet reactivity during dual therapy with aspirin and clopidogrel and clinical outcomes after successful coronary drug-eluting stent implantation...
  4. doi request reprint Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial
    Gregg F Rosner
    New York Presbyterian Hospital, Columbia University Medical Center, Cardiovascular Research Foundation, NY 10022, USA
    Circulation 125:2613-20. 2012
    ..The clinical significance of incomplete coronary revascularization (ICR) after percutaneous coronary intervention in patients with acute coronary syndromes is unknown...
  5. doi request reprint Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial
    Gregg W Stone
    Columbia University Medical Center and New York Presbyterian Hospital, New York, New York 10022, USA
    JAMA 307:1817-26. 2012
    ..Two strategies proposed to reduce distal embolization and improve outcomes after primary PCI are bolus intracoronary abciximab and manual aspiration thrombectomy...
  6. doi request reprint Impact of major bleeding and blood transfusions after cardiac surgery: analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    Am Heart J 163:522-9. 2012
    ..Prior retrospective studies have identified a relationship between bleeding after cardiac surgery and subsequent mortality. Whether this is attributable to bleeding, anemia, or transfusions is undetermined...
  7. ncbi request reprint Effect of prolonged thienopyridine use after drug-eluting stent implantation (from the TAXUS landmark trials data)
    Gregg W Stone
    The Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 102:1017-22. 2008
    ....
  8. ncbi request reprint Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial
    Gregg W Stone
    Department of Cardiology, Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10032, USA
    JAMA 295:1253-63. 2006
    ..The effectiveness of drug-eluting stents in this setting has not been established...
  9. doi request reprint Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction
    Gregg W Stone
    Columbia University Medical Center, New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY 10022, USA
    Circ Cardiovasc Interv 2:366-75. 2009
    ..Posthoc subgroup analysis from a previous trial (AMIHOT I) suggested that intracoronary delivery of supersaturated oxygen (SSO(2)) may reduce infarct size in patients with large ST-segment elevation myocardial infarction treated early...
  10. ncbi request reprint Bivalirudin for patients with acute coronary syndromes
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    N Engl J Med 355:2203-16. 2006
    ..We evaluated the role of thrombin-specific anticoagulation with bivalirudin in such patients...
  11. doi request reprint Randomized trials, statistics, and clinical inference
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10023, USA
    J Am Coll Cardiol 55:428-31. 2010
    ..It is hoped that the principles embodied in the present commentary will spur improved design of future randomized trials and thoughtful critical appraisal by health care providers...
  12. ncbi request reprint Facilitated angioplasty: paradise lost
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10032, USA
    Lancet 367:543-6. 2006
  13. ncbi request reprint Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II
    Gregg W Stone
    Columbia University Medical Center, The Cardiovascular Research Foundation, New York, NY 10022, USA
    Circulation 112:2530-7. 2005
  14. ncbi request reprint Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I
    Gregg W Stone
    Columbia University Medical Center, Cardiovascular Research Foundation, New York, NY 10022, USA
    Circulation 112:2364-72. 2005
  15. doi request reprint Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial
    Gregg W Stone
    Columbia University Medical Center New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, New York 10022, USA
    J Am Coll Cardiol 56:1597-604. 2010
    ....
  16. ncbi request reprint Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial
    Gregg W Stone
    Department of Cardiology, Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY 10032, USA
    JAMA 294:1215-23. 2005
    ..Compared with bare metal stents, drug-eluting stents reduce restenosis in noncomplex lesions. The utility of drug-eluting stents has not been evaluated in more difficult stenoses...
  17. ncbi request reprint Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    N Engl J Med 356:998-1008. 2007
    ..Such studies have been inconclusive because of their insufficient size, the use of historical controls, a limited duration of follow-up, and a lack of access to original source data...
  18. ncbi request reprint Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    JAMA 297:591-602. 2007
    ..The preferred approach is undetermined...
  19. doi request reprint Angioplasty strategies in ST-segment-elevation myocardial infarction: part II: intervention after fibrinolytic therapy, integrated treatment recommendations, and future directions
    Gregg W Stone
    Columbia University Medical Center, 111 E 59th St, 11th Floor, New York, NY 10022, USA
    Circulation 118:552-66. 2008
  20. doi request reprint Angioplasty strategies in ST-segment-elevation myocardial infarction: part I: primary percutaneous coronary intervention
    Gregg W Stone
    Columbia University Medical Center, 111 E 59th St, 11th Floor, New York, NY 10022, USA
    Circulation 118:538-51. 2008
  21. doi request reprint Bivalirudin during primary PCI in acute myocardial infarction
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    N Engl J Med 358:2218-30. 2008
    ..The safety and efficacy of bivalirudin in high-risk patients are unknown...
  22. doi request reprint Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery L
    Gregg W Stone
    Columbia University Medical Center, Cardiovascular Research Foundation, 111 E 59th St, 11th Floor, New York, NY 10022, USA
    Circulation 119:680-6. 2009
    ..The safety and efficacy of EES after 1 year have not been reported...
  23. ncbi request reprint Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial
    Gregg W Stone
    Columbia University Medical Center, The Cardiovascular Research Foundation, 111 E 59th St, 11th Floor, New York, NY 10022, USA
    JAMA 299:1903-13. 2008
    ....
  24. ncbi request reprint Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10022, USA
    JAMA 298:2497-506. 2007
    ....
  25. ncbi request reprint Predictors of infarct size after primary coronary angioplasty in acute myocardial infarction from pooled analysis from four contemporary trials
    Gregg W Stone
    Columbia University Medical Center, Cardiovascular Research Foundation, New York City, NY, USA
    Am J Cardiol 100:1370-5. 2007
    ....
  26. ncbi request reprint Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation
    Gregg W Stone
    Columbia University Medical Center, The Cardiovascular Research Foundation, 111 E 59th St, 11th Floor, New York, NY 10022, USA
    Circulation 115:2842-7. 2007
    ..We hypothesized that the prevention of restenosis-related adverse events by drug-eluting stents might offset some or all of the excess risk from ST...
  27. ncbi request reprint Non-ST-elevation acute coronary syndromes
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 1022, USA
    Lancet 369:801-3. 2007
  28. ncbi request reprint Percutaneous recanalization of chronically occluded coronary arteries: procedural techniques, devices, and results
    Gregg W Stone
    Division of Cardiology, Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10022, USA
    Catheter Cardiovasc Interv 66:217-36. 2005
  29. doi request reprint Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease
    Gregg W Stone
    Columbia University Medical Center New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY 10022, USA
    N Engl J Med 362:1663-74. 2010
    ..Previous studies have established the superiority of coronary everolimus-eluting stents over paclitaxel-eluting stents with respect to angiographic findings. However, these trials were not powered for superiority in clinical end points...
  30. ncbi request reprint Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial
    Gregg W Stone
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY 10022, USA
    JAMA 293:1063-72. 2005
    ....
  31. ncbi request reprint Systemic hypothermia to prevent radiocontrast nephropathy (from the COOL-RCN Randomized Trial)
    Gregg W Stone
    Columbia University Medical Center New York Presbyterian Hospital, Cardiovascular Research Foundation, New York, USA
    Am J Cardiol 108:741-6. 2011
    ..97, 95% confidence interval 0.47 to 1.98, p = 0.93). In conclusion, in patients with CKD undergoing invasive cardiology procedures, systemic hypothermia is safe but is unlikely to prevent RCN...
  32. doi request reprint Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program
    Gregg W Stone
    Department of Cardiology, Columbia University, Medical Center New York Presbyterian Hospital, New York, New York 10022, USA
    JACC Cardiovasc Interv 4:530-42. 2011
    ..These studies sought to evaluate the clinical outcomes of the slow-release Taxus paclitaxel-eluting stent (PES) versus an otherwise identical bare-metal stent (BMS)...
  33. doi request reprint Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial
    Gregg W Stone
    Columbia University Medical Center New York Presbyterian Hospital and the Cardiovascular Research Foundation, 111 East 59th Street, New York, NY 10022, USA
    J Am Coll Cardiol 58:19-25. 2011
    ....
  34. doi request reprint A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Cor
    Gregg W Stone
    Columbia University Medical Center New York Presbyterian Hospital and the Cardiovascular Research Foundation, 111 East 59th Street, New York, NY 10022, USA
    J Am Coll Cardiol 57:1700-8. 2011
    ....
  35. doi request reprint 5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial
    Gregg W Stone
    Department of Medicine, Division of Cardiology, Columbia University, Medical Center New York Presbyterian Hospital, Cardiovascular Research Foundation, New York 10022, USA
    JACC Cardiovasc Interv 4:300-9. 2011
    ..We sought to evaluate the utility of the JOSTENT polytetrafluoroethylene (PTFE) stent-graft (Jomed GmbH, Rangendingen, Germany) in patients with diseased saphenous vein grafts (SVGs) undergoing percutaneous coronary intervention (PCI)...
  36. doi request reprint A prospective natural-history study of coronary atherosclerosis
    Gregg W Stone
    Columbia University Medical Center New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY 10022, USA
    N Engl J Med 364:226-35. 2011
    ..Atherosclerotic plaques that lead to acute coronary syndromes often occur at sites of angiographically mild coronary-artery stenosis. Lesion-related risk factors for such events are poorly understood...
  37. doi request reprint Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus
    Gregg W Stone
    New York Presbyterian Hospital, Columbia University Medical Center, The Cardiovascular Research Foundation, New York, NY 10022, USA
    Circulation 124:893-900. 2011
    ..These studies lacked sufficient power to examine individual safety and efficacy end points...
  38. doi request reprint Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction
    Gregg W Stone
    Columbia University Medical Center and New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY 10022, USA
    N Engl J Med 360:1946-59. 2009
    ....
  39. doi request reprint Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial
    Gregg W Stone
    New York Presbyterian Hospital, Columbia University Medical Center, New York, NY 10022, USA
    Lancet 377:2193-204. 2011
    ..Primary results of the HORIZONS-AMI trial have been previously reported. In this final report, we aimed to assess 3-year outcomes...
  40. doi request reprint Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial)
    Kenichi Tsujita
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 105:1385-94. 2010
    ..Paradoxically, in this post hoc analysis, the reductions in major bleeding and mortality in ST elevation myocardial infarction afforded by bivalirudin occurred primarily in patients without baseline anemia...
  41. doi request reprint Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY)
    Roxana Mehran
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York 10032, USA
    JACC Cardiovasc Interv 2:748-57. 2009
    ....
  42. ncbi request reprint A risk score to predict bleeding in patients with acute coronary syndromes
    Roxana Mehran
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York 10032, USA
    J Am Coll Cardiol 55:2556-66. 2010
    ..The aim of this study was to develop a practical risk score to predict the risk and implications of major bleeding in acute coronary syndromes (ACS)...
  43. doi request reprint Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial
    Eugenia Nikolsky
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10022, USA
    J Am Coll Cardiol 54:1293-302. 2009
    ..We assessed the incidence, predictors, and outcomes of gastrointestinal bleeding (GIB) in patients with acute coronary syndromes (ACS)...
  44. doi request reprint Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial)
    Alexandra J Lansky
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 103:1196-203. 2009
    ..In women, bivalirudin monotherapy compared with a GPI-based strategy resulted in significantly decreased bleeding but similar rates of 1-year composite ischemia and mortality...
  45. doi request reprint Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials
    Hiroshi Doi
    Cardiovascular Research Foundation and Columbia University Medical Center, New York, New York 10022, USA
    JACC Cardiovasc Interv 2:1269-75. 2009
    ..We investigated the predictive value of the intravascular ultrasound (IVUS) measured post-intervention minimum stent area (MSA) on 9-month follow-up paclitaxel-eluting stent (PES) patency compared with bare-metal stents (BMS)...
  46. doi request reprint Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial In
    Adam J Saltzman
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    JACC Cardiovasc Interv 4:1011-9. 2011
    ..This study sought to investigate the impact of chronic kidney disease (CKD) in patients undergoing percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) with different antithrombotic strategies...
  47. doi request reprint Impact of smoking on outcomes of patients with ST-segment elevation myocardial infarction (from the HORIZONS-AMI Trial)
    Kenji Goto
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 108:1387-94. 2011
    ..Bivalirudin monotherapy compared to UFH plus a GPI decreased major bleeding regardless of smoking status but may have different effects on individual components of ischemic events...
  48. ncbi request reprint Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale
    Gregg W Stone
    Columbia University Medical Center, Cardiovascular Research Foundation, New York, NY 10022, USA
    Am Heart J 148:764-75. 2004
    ..Pilot trials suggest that the thrombin-specific anticoagulant bivalirudin may improve clinical outcomes in ACS...
  49. doi request reprint The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale
    Roxana Mehran
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10032, USA
    Am Heart J 156:44-56. 2008
    ..Newer pharmacologic agents and drug-eluting stents may address both of these issues...
  50. doi request reprint Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction
    George D Dangas
    Cardiovascular Institute, Mount Sinai Medical Center, One Gustave L Levy Place, New York, NY 10029, USA
    Circulation 123:1745-56. 2011
    ..Concerns persist regarding the risk of stent thrombosis in the setting of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction...
  51. ncbi request reprint Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited
    Giora Weisz
    Cardiovascular Research Foundation and Center for Interventional Therapy, New York, NY, USA
    Am Heart J 150:358-64. 2005
    ..We sought to determine the relationship between cigarette smoking and outcomes after mechanical reperfusion therapy in acute myocardial infarction (AMI)...
  52. ncbi request reprint Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention
    Eugenia Nikolsky
    Cardiovascular Research Foundation, and Lenox Hill Heart and Vascular Institute, New York, New York, USA
    Am J Cardiol 94:300-5. 2004
    ..Contrast-induced nephropathy was among the independent predictors of a 1-year mortality rate (OR 2.75, p <0.001)...
  53. doi request reprint Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
    Roxana Mehran
    Columbia University Medical Center New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY, USA
    Lancet 374:1149-59. 2009
    ..Here, we assess whether these initial benefits were maintained at 1 year of follow-up...
  54. doi request reprint Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent int
    Roxana Mehran
    Department of Cardiology, Mount Sinai Medical Center, New York, New York, USA
    JACC Cardiovasc Interv 4:654-64. 2011
    ..This study sought to develop a risk score predictive of bleeding in patients undergoing percutaneous coronary intervention (PCI) and to investigate the impact of bleeding on subsequent mortality...
  55. doi request reprint Gender and the extent of coronary atherosclerosis, plaque composition, and clinical outcomes in acute coronary syndromes
    Alexandra J Lansky
    Yale University Medical Center, Division of Cardiology, New Haven, Connecticut, USA
    JACC Cardiovasc Imaging 5:S62-72. 2012
    ..This study sought to assess the extent and composition of atherosclerosis contributing to acute coronary syndrome events in women compared with men...
  56. doi request reprint Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial
    Alexandra J Lansky
    Columbia University Medical Center, Department of Cardiology, Cardiovascular Research Foundation, New York, New York 10022, USA
    Catheter Cardiovasc Interv 72:917-24. 2008
    ..The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI)...
  57. ncbi request reprint Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era
    Tereza Pucelikova
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY, USA
    Am J Cardiol 101:63-8. 2008
    ..025). In conclusion, our data show that patients with SVG lesions remain a high-risk subgroup with worse outcomes after percutaneous coronary intervention compared with native vessel disease even in the era of drug-eluting stents...
  58. ncbi request reprint Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial
    Eugenia Nikolsky
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10032, USA
    JACC Cardiovasc Interv 2:624-32. 2009
    ..We sought to determine the relationship between red blood cell (RBC) transfusion and clinical outcomes in patients undergoing primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI)...
  59. doi request reprint Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent
    Bimmer E Claessen
    New York Presbyterian Hospital, Columbia University, New York, NY, USA
    JACC Cardiovasc Interv 4:1209-15. 2011
    ..The aim of this study was to investigate the impact of reference vessel diameter (RVD) and lesion length (LL) on the relative safety and efficacy of everolimus-eluting stents (EES) and paclitaxel-eluting stents (PES)...
  60. ncbi request reprint Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial)
    Eugenia Nikolsky
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 99:1055-61. 2007
    ..03, 95% CI 1.00 to 1.06, p = 0.055) at 1 year. In conclusion, a higher baseline platelet count in patients with AMI is a powerful independent predictor of death and reinfarction within the first year after primary PCI...
  61. ncbi request reprint Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial
    Eugenia Nikolsky
    Cardiovascular Research Foundation, New York, New York 10022, USA
    J Am Coll Cardiol 44:547-53. 2004
    ..We sought to investigate the impact of anemia in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI)...
  62. doi request reprint Intravascular ultrasound comparison of the retrograde versus antegrade approach to percutaneous intervention for chronic total coronary occlusions
    Kenichi Tsujita
    Cardiovascular Research Foundation and Columbia University Medical Center, New York, New York 10022, USA
    JACC Cardiovasc Interv 2:846-54. 2009
    ..We sought to evaluate the results of the antegrade versus retrograde chronic total occlusion (CTO) technique with intravascular ultrasound (IVUS) imaging...
  63. doi request reprint Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial
    George Dangas
    Columbia University Medical Center, New York, New York Cardiovascular Research Foundation, New York, New York 10022, USA
    J Am Coll Cardiol 54:1438-46. 2009
    ....
  64. ncbi request reprint Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation
    Hideo Takebayashi
    Cardiovascular Research Foundation, Lenox Hill Heart and Vascular Institute, New York, NY 10022, USA
    Circulation 110:3430-4. 2004
    ..Little is known about causes of intimal hyperplasia (IH) after sirolimus-eluting stent (SES) implantation...
  65. doi request reprint Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent)
    Stephen G Ellis
    Cleveland Clinic, Department of Cardiology, Cleveland, Ohio 44195, USA
    JACC Cardiovasc Interv 2:1248-59. 2009
    ....
  66. ncbi request reprint One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial
    Gregg W Stone
    The Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, 55 E 59th St, 6th Floor, New York, NY 10022, USA
    Circulation 109:1942-7. 2004
    ..The safety and efficacy of the slow-release, polymer-based, paclitaxel-eluting stent after implantation in a broad cross section of de novo coronary lesions at 1 year are unknown...
  67. ncbi request reprint Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease
    Ajay J Kirtane
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    JACC Cardiovasc Interv 2:967-76. 2009
    ..Natick, Massachusetts) in the 477 patients with diabetes mellitus (DM) enrolled in the randomized ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease) trial...
  68. doi request reprint Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic End
    Martin B Leon
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10032, USA
    JACC Cardiovasc Interv 2:1208-18. 2009
    ..The aim of this study was to assess, after 2 years of follow-up, the safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent (ZES) compared with a paclitaxel-eluting stent (PES) in patients with native coronary lesions...
  69. ncbi request reprint Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial
    Alexandra J Lansky
    Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, 55 E 59th St, 6th Floor, New York, NY 10022 1112, USA
    Circulation 109:1948-54. 2004
    ..The DELIVER trial was a prospective, randomized, blinded, multicenter clinical evaluation of the non-polymer-based paclitaxel-coated ACHIEVE stent compared with the stainless steel Multi-Link (ML) PENTA stent...
  70. ncbi request reprint A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease
    Gregg W Stone
    Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, New York 10022, USA
    N Engl J Med 350:221-31. 2004
    ..Restenosis after coronary stenting necessitates repeated percutaneous or surgical revascularization procedures. The delivery of paclitaxel to the site of vascular injury may reduce the incidence of neointimal hyperplasia and restenosis...
  71. doi request reprint A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial
    Martin B Leon
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    J Am Coll Cardiol 55:543-54. 2010
    ....
  72. doi request reprint Impact of leukocyte count on mortality and bleeding in patients with myocardial infarction undergoing primary percutaneous coronary interventions: analysis from the Harmonizing Outcome with Revascularization and Stent in Acute Myocardial Infarction trial
    Tullio Palmerini
    Istituto Cardiologia, Policlinico S Orsola, Bologna, Italy
    Circulation 123:2829-37, 7 p following 2837. 2011
    ..Furthermore, whether there is a relationship between WBCc and risk of noncardiac mortality and bleeding after percutaneous coronary intervention is unknown...
  73. ncbi request reprint Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) tr
    Alexandra J Lansky
    College of Physicians and Surgeons, Columbia University, and the Cardiovascular Research Foundation, New York, NY 10022, USA
    Circulation 111:1611-8. 2005
    ..Whether contemporary interventional treatment strategies have improved outcomes for women compared with men is unknown...
  74. ncbi request reprint Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
    Sigmund Silber
    Kardiologische Praxis und Praxisklinik, Munchen, Germany
    Eur Heart J 26:804-47. 2005
    ....
  75. ncbi request reprint Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial
    Gregg W Stone
    Cardiovascular Research Foundation, Lenox Hill Heart and Vascular Institute, New York, NY 10022, USA
    Circulation 105:2347-54. 2002
    ..Also unknown is whether the acuity of the presenting clinical syndrome, which may affect the degree of platelet inhibition required or achieved, influences the response to different antiplatelet agents...
  76. ncbi request reprint Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease
    Alexandra J Lansky
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York, USA
    J Am Coll Cardiol 45:1180-5. 2005
    ..We sought to determine whether gender influences the results of paclitaxel-eluting stent implantation...
  77. ncbi request reprint Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery
    George Dangas
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York, USA
    J Am Coll Cardiol 45:1186-92. 2005
    ..We sought to examine the efficacy of paclitaxel-eluting stent implantation in the left anterior descending coronary artery (LAD)...
  78. ncbi request reprint Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial)
    Eugenia Nikolsky
    Cardiovascular Research Foundation, New York, New York 10022, USA
    Am J Cardiol 95:709-15. 2005
    ..Paclitaxel-eluting stents attenuate the increased risk associated with obesity, such that the intermediate-term prognosis after percutaneous coronary intervention is independent of weight...
  79. ncbi request reprint Successful use of the frontrunner catheter in the treatment of in-stent coronary chronic total occlusions
    Yi ming Yang
    Columbia University Medical Center and Cardiovascular Research Foundation, 161 Fort Washington Avenue, New York, NY 10032, USA
    Catheter Cardiovasc Interv 63:462-8. 2004
    ..TIMI 3 flow was achieved in all target vessels after further balloon angioplasty or stenting. The Frontrunner device is a safe and effective tool in the treatment of CTOs from ISR...
  80. ncbi request reprint Polymer-based paclitaxel-eluting stents in percutaneous coronary intervention: a review of the TAXUS trials
    Amir Halkin
    Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, 55 E 59th Street, New York City, NY 10022, USA
    J Interv Cardiol 17:271-82. 2004
    ..5-3.75 mm in diameter. Additional trials in the TAXUS program are currently examining the role of slow and moderate rate-release polymer-based, paclitaxel-eluting stents in a broader range of clinical settings and lesion subsets...
  81. ncbi request reprint Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial
    Giulio Guagliumi
    Ospedali Riuniti di Bergamo, Bergamo, Italy
    Circulation 110:1598-604. 2004
    ....
  82. ncbi request reprint Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library
    John L Petersen
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 148:269-76. 2004
    ..It is hoped that the SYNERGY Library will serve as a model for future substudy design to maximize academic insight within the framework of a large-scale, multicenter trial...
  83. ncbi request reprint Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model
    Nicholas N Kipshidze
    Lenox Hill Heart and Vascular Institute and Cardiovascular Research Foundation, New York, New York 10021, USA
    Catheter Cardiovasc Interv 61:518-27. 2004
    ..In the porcine coronary model, an advanced c-myc-eluting PC stent blocked c-myc expression and significantly inhibited myointimal hyperplasia and allowed complete reendothelialization and healing response...
  84. ncbi request reprint Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials
    David E Kandzari
    Division of Cardiology, Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 147:457-62. 2004
    ....
  85. ncbi request reprint Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial
    Ameet Bakhai
    Harvard Clinical Research Institute, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, Mass 02215, USA
    Circulation 108:2857-63. 2003
    ..Both stenting and the glycoprotein IIb/IIIa inhibitor abciximab improve outcomes for patients undergoing primary angioplasty for acute myocardial infarction (AMI). However, the cost-effectiveness of these strategies is unknown...
  86. ncbi request reprint Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET)
    Albert W Chan
    Department of Cardiology, Ochsner Clinic Foundation, New Orleans, Louisiana, USA
    J Am Coll Cardiol 42:1188-95. 2003
    ..We sought to examine if clopidogrel treatment initiated before coronary stenting improved clinical outcomes among patients receiving aspirin and a glycoprotein (GP) IIb/IIIa inhibitor...
  87. ncbi request reprint Influence of stent length to lesion length ratio on angiographic and clinical outcomes after implantation of bare metal and drug-eluting stents (the TAXUS-IV Study)
    S Chiu Wong
    Weill Medical College of Cornell University, New York, New York 10021, USA
    Am J Cardiol 95:1043-8. 2005
    ..86, p = 0.76, and hazard ratio 0.58, p = 0.21, respectively). These data do not support the arbitrary use of larger ratios of stent length to lesion length in patients who undergo implantation of drug-eluting stents...
  88. ncbi request reprint [Guidelines for percutaneous coronary interventions]
    Sigmund Silber
    Rev Esp Cardiol 58:679-728. 2005
  89. ncbi request reprint [Guidelines for percutaneous coronary interventions]
    Sigmund Silber
    Ital Heart J Suppl 6:427-74. 2005
  90. ncbi request reprint Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Tria
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    J Am Coll Cardiol 52:807-14. 2008
    ..This study was designed to determine the impact of bivalirudin on 1-year outcomes in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI)...
  91. ncbi request reprint Clinical outcomes after heterogeneous overlap stenting with drug-eluting stents and bare-metal stents for de novo coronary artery narrowings
    Jiro Aoki
    Center for Interventional Vascular Therapy, Columbia University Medical Center, New York, NY, USA
    Am J Cardiol 101:58-62. 2008
    ..In conclusion, the incidence of DES and BMS overlap stenting is rare in daily practice, but this procedure is associated with a high rate of target vessel revascularization...
  92. ncbi request reprint Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgen
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    J Am Coll Cardiol 51:1734-41. 2008
    ..The aim of this study was to compare outcomes in patients receiving consistent unfractionated heparin (UFH)/enoxaparin (ENOX) therapy and in those switched at randomization to bivalirudin monotherapy...
  93. ncbi request reprint Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial
    Frederick Feit
    Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA
    J Am Coll Cardiol 51:1645-52. 2008
    ..We sought to evaluate clinical outcomes of patients with diabetes mellitus in the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial, overall and by treatment arm...
  94. doi request reprint Effectiveness of drug-eluting stent implantation for patients with unprotected left main coronary artery stenosis
    Young Hak Kim
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 101:801-6. 2008
    ..However, bifurcation stenosis remains a significant predictor of unfavorable clinical outcome...
  95. ncbi request reprint The truth and consequences of the COURAGE trial
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center the Lindner Research Center, Cincinnati, Ohio 45219, USA
    J Am Coll Cardiol 50:1598-603. 2007
    ..An in-depth analysis of the COURAGE trial design and execution is provided...
  96. ncbi request reprint Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1043-51. 2007
    ..This study sought to study stent thrombosis with the paclitaxel-eluting Taxus stent...
  97. ncbi request reprint Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: a meta-analysis of randomized trials
    Giuseppe De Luca
    Division of Cardiology, Ospedale Maggiore della Carita, Universite del Piemonte Orientale, Novara, Italy
    Am Heart J 153:343-53. 2007
    ..The aim of this meta-analysis was to combine data from all randomized trials conducted with adjunctive mechanical devices to prevent distal embolization in AMI...
  98. ncbi request reprint Intravascular ultrasound assessment of drug-eluting stent expansion
    Jose de Ribamar Costa
    Cardiovascular Research Foundation and Columbia University Medical Center, New York, NY, USA
    Am Heart J 153:297-303. 2007
    ....
  99. ncbi request reprint An overview of the TAXUS Express, paclitaxel-eluting stent clinical trial program
    John M Lasala
    Division of Cardiology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Interv Cardiol 19:422-31. 2006
    ....
  100. ncbi request reprint Outcome after acute incomplete sirolimus-eluting stent apposition as assessed by serial intravascular ultrasound
    Masashi Kimura
    The Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York, USA
    Am J Cardiol 98:436-42. 2006
    ..Although most ISAs after SES implantation do not resolve completely, the incidence of restenosis or thrombosis is not affected...
  101. ncbi request reprint Prediction of one-year mortality among 30-day survivors after primary percutaneous coronary interventions
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 97:817-22. 2006
    ....